EP0046661B1 - Rapamycin derivatives - Google Patents
Rapamycin derivatives Download PDFInfo
- Publication number
- EP0046661B1 EP0046661B1 EP81303794A EP81303794A EP0046661B1 EP 0046661 B1 EP0046661 B1 EP 0046661B1 EP 81303794 A EP81303794 A EP 81303794A EP 81303794 A EP81303794 A EP 81303794A EP 0046661 B1 EP0046661 B1 EP 0046661B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- rapamycin
- monoacetyl
- derivatives
- derivative
- diacetyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- This invention relates to novel monoacetyl and diacetyl derivatives of rapamycin, to processes for their preparation, to methods of using the derivatives and to pharmaceutical compositions of the derivatives.
- the derivatives are useful as antifungal antibiotics.
- Rapamycin is an antifungal antibiotic described by C. Vezina et al., J. Antibiot., 28, 721 (1975), S. N. Sehgal et al., J. Antibiot., 28, 727 (1975), S. N. Sehgal et al., U.S. Patent 3,929,992, issued December 30th, 1975 and S. N. Sehgal et al., U.S. Patent 3,993,749, issued November 23, 1976. The latter two patents are herein incorporated by reference. The structure of rapamycin is described by D. C. Neil, et al., Can. J. Chem., 56, 2491 (1978).
- Rapamycin is extracted from a streptomycete (Streptomyces hygroscopicus NRRL 5491) isolated from an Easter Island soil sample and is particularly effective against Candida albicans both in vitro and in vivo, H. A. Baker et al., J. Antibiot., 31, 539 (1978). Streptomyces hygroscopicus NRRL 5491 samples were deposited 23rd June 1972 without restrictions with the Northern Utilization and Research Division, Agricultural Research Service, U.S. Department of Agriculture, Peoria, Illinois, U.S.A. A report by R. R. Martel et al., Can. J.
- rapamycin for the prevention of the development of experimental immunopathies. Recently, rapamycin was shown to be an effective agent for treating carcinogenic tumors in a mammal by S. N. Sehgal and C. Vezina, United States Patent Application Serial No. 957,626, filed November 3, 1978. In Belgium, a corresponding application of the latter application issued as Belgium Patent No. 877,700 on January 14, 1980.
- This invention provides monoacetyl or diacetyl derivatives of rapamycin.
- An antifungal composition comprising a monoacetyl or diacetyl derivative of rapamycin and a carrier.
- the carrier is a pharmaceutically acceptable carrier.
- the monoacetyl and diacetyl derivatives of rapamycin inhibit the growth of pathogenic fungi in a mammal by administering to the mammal an effective antifungal amount of the monoacetyl or diacetyl derivative of rapamycin.
- organic proton acceptor means the organic bases or amines, for instance, triethylamine, pyridine, N-ethylmorpholine, 1,5-diazabicyclo[4.3.0]non-5-ene and the like.
- the monoacetyl and diacetyl derivatives of rapamycin are useful as antifungal agents against pathogenic fungi; for example, Candida albicans.
- the inhibitory activity of the derivatives are especially pronounced against Candida albicans.
- the monoacetyl derivative exhibits a MIC of 0.04 mcg/ml and the diacetyl derivative exhibits a MIC of 2.5 mcg/ml.
- the antifungal activity of the derivatives are demonstrated in standard tests used for this purpose, for example, in the tests described in "Antiseptics, Disinfectants, Fungicides and Sterilization", G. F. Reddish, Ed., 2nd ed., Lea and Febiger, Philadelphia, 1957 or by D. C. Grove and W. A. Randall in "Assay Methods of Antibiotics", Med. Encyl. Inc., New York 1955.
- rapamycin derivative of this invention When employed as an antifungal agent in a mammal, it can be used alone or in combination with pharmaceutically acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard biological practice.
- an antifungally effective amount of the derivative can be administered orally in solid form containing such excipients as starch, sugar, certain types of clay and so forth.
- such an amount can be administered orally in the form of solutions or suspensions or the derivative can be injected parenterally.
- the derivative can be used in the form of a sterile solution or suspension containing other solutes or suspending agents, for example, enough saline or glucose to make the solution isotonic, bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
- solutes or suspending agents for example, enough saline or glucose to make the solution isotonic, bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
- the dosage of the present derivative will vary with the form of administration and the particular derivative chosen. Furthermore, it will vary with the particular host under treatment. Generally, treatment is initiated with small dosages substantially less then the optimum dose of the derivative. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
- the derivative of this invention is most desirably administered at a concentration level that will generally afford antifungally effective results without causing any harmful or deleterious side effects and preferably at a level that is in a range of from about 1.0 mg to about 250 mg per kilo per day, although as aforementioned variations will occur.
- a dosage level that is in the range of from about 10 mg to about 100 mg per kilo per day is most desirably employed in order to achieve effective results.
- the derivative can be employed topically.
- topical application it may be formulated in the form of solutions, creams or lotions in pharmaceutically acceptable vehicles containing 0.1-5 per cent, preferably 2 per cent of the agent, and may be administered topically to the infected area of the skin.
- the derivative also can be used for cleaning and disinfecting laboratory equipment, surgical instruments, locker rooms, or shower rooms of sensitive fungus organisms.
- an alkanol having 1 to 6 carbon atoms preferably methanol
- a non-ionic surface-active agent for example, polysorbate 80 U.S.P.
- the monoacetyl and diacetyl derivatives of rapamycin can be useful as anticancer or antitumour agents.
- the derivatives can be used to treat carcinogenic tumors in a mammal by administering to the mammal an antitumour effective amount of the derivative. More specifically, the derivatives can reduce tumor size in and prolong survival time of a tumor bearing mammal. The effectiveness of the derivatives in this respect can be demonstrated in the laboratory with rodents having transplanted tumors. Details of methods used to evaluate this effect are described in various publications; for example, R. I. Geran et al., Cancer Chemother. Rep., Part 3, 3, (No. 2) 1-103 (1972) and references therein. In addition, the protocols for the antitumour tests are available from the National Cancer Institute, Bethesda, Maryland, U.S.A. The mode of administration and compositions of the derivatives are similar to those described above for antifungal use.
- the acetyl derivatives of rapamycin are prepared by the acetylation of rapamycin. Accordingly this invention provides a process for preparing a mono- or di-acetyl derivative of rapamycin which comprises acetylating rapamycin with an acetylating agent containing an acetyl group.
- Acetylation of rapamycin may be carried out with an agent selected from acetyl iodide, bromide or chloride in the presence of an organic proton acceptor, preferably triethylamine or pyridine, for example at 0 to 50°C or 0.5 to 10 hours, to give the corresponding monoacetyl or diacetyl derivative of rapamycin.
- a preferred method of acetylation is the reaction of rapamycin with acetic anhydride in an excess of the organic proton acceptor at 0 to 10°C for about one to three hours to obtain a separable mixture of the monoacetyl and diacetyl derivatives of rapamycin.
Abstract
Description
- This invention relates to novel monoacetyl and diacetyl derivatives of rapamycin, to processes for their preparation, to methods of using the derivatives and to pharmaceutical compositions of the derivatives. The derivatives are useful as antifungal antibiotics.
- Rapamycin is an antifungal antibiotic described by C. Vezina et al., J. Antibiot., 28, 721 (1975), S. N. Sehgal et al., J. Antibiot., 28, 727 (1975), S. N. Sehgal et al., U.S. Patent 3,929,992, issued December 30th, 1975 and S. N. Sehgal et al., U.S. Patent 3,993,749, issued November 23, 1976. The latter two patents are herein incorporated by reference. The structure of rapamycin is described by D. C. Neil, et al., Can. J. Chem., 56, 2491 (1978). Rapamycin is extracted from a streptomycete (Streptomyces hygroscopicus NRRL 5491) isolated from an Easter Island soil sample and is particularly effective against Candida albicans both in vitro and in vivo, H. A. Baker et al., J. Antibiot., 31, 539 (1978). Streptomyces hygroscopicus NRRL 5491 samples were deposited 23rd June 1972 without restrictions with the Northern Utilization and Research Division, Agricultural Research Service, U.S. Department of Agriculture, Peoria, Illinois, U.S.A. A report by R. R. Martel et al., Can. J. Physiol., 55, 48 (1977) describes the use of rapamycin for the prevention of the development of experimental immunopathies. Recently, rapamycin was shown to be an effective agent for treating carcinogenic tumors in a mammal by S. N. Sehgal and C. Vezina, United States Patent Application Serial No. 957,626, filed November 3, 1978. In Belgium, a corresponding application of the latter application issued as Belgium Patent No. 877,700 on January 14, 1980.
- This invention provides monoacetyl or diacetyl derivatives of rapamycin.
- An antifungal composition is also provided comprising a monoacetyl or diacetyl derivative of rapamycin and a carrier. For pharmaceutical applications the carrier is a pharmaceutically acceptable carrier.
- The monoacetyl and diacetyl derivatives of rapamycin inhibit the growth of pathogenic fungi in a mammal by administering to the mammal an effective antifungal amount of the monoacetyl or diacetyl derivative of rapamycin.
- The term "organic proton acceptor" as used herein means the organic bases or amines, for instance, triethylamine, pyridine, N-ethylmorpholine, 1,5-diazabicyclo[4.3.0]non-5-ene and the like.
- The monoacetyl and diacetyl derivatives of rapamycin are useful as antifungal agents against pathogenic fungi; for example, Candida albicans. The inhibitory activity of the derivatives are especially pronounced against Candida albicans. Against this fungi, the monoacetyl derivative exhibits a MIC of 0.04 mcg/ml and the diacetyl derivative exhibits a MIC of 2.5 mcg/ml.
- The antifungal activity of the derivatives are demonstrated in standard tests used for this purpose, for example, in the tests described in "Antiseptics, Disinfectants, Fungicides and Sterilization", G. F. Reddish, Ed., 2nd ed., Lea and Febiger, Philadelphia, 1957 or by D. C. Grove and W. A. Randall in "Assay Methods of Antibiotics", Med. Encyl. Inc., New York 1955.
- When the rapamycin derivative of this invention is employed as an antifungal agent in a mammal, it can be used alone or in combination with pharmaceutically acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard biological practice. For example, an antifungally effective amount of the derivative can be administered orally in solid form containing such excipients as starch, sugar, certain types of clay and so forth. Similarly, such an amount can be administered orally in the form of solutions or suspensions or the derivative can be injected parenterally. For parenteral administration the derivative can be used in the form of a sterile solution or suspension containing other solutes or suspending agents, for example, enough saline or glucose to make the solution isotonic, bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
- The dosage of the present derivative will vary with the form of administration and the particular derivative chosen. Furthermore, it will vary with the particular host under treatment. Generally, treatment is initiated with small dosages substantially less then the optimum dose of the derivative. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. In general the derivative of this invention is most desirably administered at a concentration level that will generally afford antifungally effective results without causing any harmful or deleterious side effects and preferably at a level that is in a range of from about 1.0 mg to about 250 mg per kilo per day, although as aforementioned variations will occur. However, a dosage level that is in the range of from about 10 mg to about 100 mg per kilo per day is most desirably employed in order to achieve effective results.
- In addition, the derivative can be employed topically. For topical application it may be formulated in the form of solutions, creams or lotions in pharmaceutically acceptable vehicles containing 0.1-5 per cent, preferably 2 per cent of the agent, and may be administered topically to the infected area of the skin.
- The derivative also can be used for cleaning and disinfecting laboratory equipment, surgical instruments, locker rooms, or shower rooms of sensitive fungus organisms. For such purposes it is preferred to use 0.1-10% solutions of the derivative in an alkanol having 1 to 6 carbon atoms, preferably methanol, diluted with 10-100 volumes of water containing 0.001-0.1 % of a non-ionic surface-active agent, for example, polysorbate 80 U.S.P., immediately before applying it to the objects to be cleaned and disinfected.
- In addition to use as an antifungal agent, the monoacetyl and diacetyl derivatives of rapamycin can be useful as anticancer or antitumour agents. The derivatives can be used to treat carcinogenic tumors in a mammal by administering to the mammal an antitumour effective amount of the derivative. More specifically, the derivatives can reduce tumor size in and prolong survival time of a tumor bearing mammal. The effectiveness of the derivatives in this respect can be demonstrated in the laboratory with rodents having transplanted tumors. Details of methods used to evaluate this effect are described in various publications; for example, R. I. Geran et al., Cancer Chemother. Rep., Part 3, 3, (No. 2) 1-103 (1972) and references therein. In addition, the protocols for the antitumour tests are available from the National Cancer Institute, Bethesda, Maryland, U.S.A. The mode of administration and compositions of the derivatives are similar to those described above for antifungal use.
- The acetyl derivatives of rapamycin are prepared by the acetylation of rapamycin. Accordingly this invention provides a process for preparing a mono- or di-acetyl derivative of rapamycin which comprises acetylating rapamycin with an acetylating agent containing an acetyl group. Acetylation of rapamycin may be carried out with an agent selected from acetyl iodide, bromide or chloride in the presence of an organic proton acceptor, preferably triethylamine or pyridine, for example at 0 to 50°C or 0.5 to 10 hours, to give the corresponding monoacetyl or diacetyl derivative of rapamycin. Replacement of the above described acetylating agent with acetic anhydride also gives the corresponding monoacetyl or diacetyl derivative of rapamycin. The above acetylations can be conducted in an inert organic solvent such as benzene, chloroform or dichloromethane or an excess of the organic proton acceptor can serve as the solvent. Use of about 0.7 to 1.5 molar equivalents of the acetylating agent gives a separable mixture of the monoacetyl and diacetyl derivatives wherein the monoacetyl derivative predominates whereas use of about 1.5 to 5 molar equivalents of the acetylating agent gives a separable mixture of the monoacetyl and diacetyl derivatives wherein the diacetyl derivative predominates. A preferred method of acetylation is the reaction of rapamycin with acetic anhydride in an excess of the organic proton acceptor at 0 to 10°C for about one to three hours to obtain a separable mixture of the monoacetyl and diacetyl derivatives of rapamycin.
- The following example illustrates further this invention:
- A solution of 300 mg of rapamycin in 5 ml of dry pyridine was cooled in an ice bath. To this solution, 2.5 ml of acetic anhydride was added and the mixture was stirred at 0 to 5°C for 2 hours. The excess of anhydride was decomposed by careful addition of methanol and the mixture was poured into ice containing 2N hydrochloric acid. The precipitated solids were extracted with ethyl acetate. The ethyl acetate extract was washed with water, dried over sodium sulphate and evaporated. The oily residue was chromatographed over silica gel using 20% ethyl acetate in benzene. The appropriate initial fractions were collected, evaporated and crystallised from chloroform-hexane to give rapamycin diacetate (0.165 g): mp 92-93°C; ir (CHCla) 3400, 1730, 1640 and 1620 cm-1; uv max (MeOH) 288 (ε=366), 227 (E=484) and 267 nm (E=363); and nmr (CDCI3) 8 2.05 (s, 3H). The appropriate later fractions were collected, evaporated and crystallised from benzene-hexane to give rapamycin monoacetate (0.058 g): mp 101-102°C; ir (CHCl3) 3400, 1730, 1640 and 1620 cm-1; uv max (MeOH) 288 (E=374), 277 (ε=494) and 267 nm (E=372); and nmr (CDCI,) 8 2.05 (s, 3H) and 2.1 (s, 3H).
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT81303794T ATE7920T1 (en) | 1980-08-25 | 1981-08-20 | RAPAMYCIN DERIVATIVES. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US181252 | 1980-08-25 | ||
US06/181,252 US4316885A (en) | 1980-08-25 | 1980-08-25 | Acyl derivatives of rapamycin |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0046661A1 EP0046661A1 (en) | 1982-03-03 |
EP0046661B1 true EP0046661B1 (en) | 1984-06-13 |
Family
ID=22663492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP81303794A Expired EP0046661B1 (en) | 1980-08-25 | 1981-08-20 | Rapamycin derivatives |
Country Status (7)
Country | Link |
---|---|
US (1) | US4316885A (en) |
EP (1) | EP0046661B1 (en) |
JP (1) | JPS57118586A (en) |
AT (1) | ATE7920T1 (en) |
CA (1) | CA1159054A (en) |
DE (1) | DE3164177D1 (en) |
IE (1) | IE51508B1 (en) |
Families Citing this family (218)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
EP0429436A3 (en) * | 1985-12-06 | 1991-12-27 | The University Of Kansas | Prodrugs of rapamycin |
US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
US5120726A (en) * | 1991-03-08 | 1992-06-09 | American Home Products Corporation | Rapamycin hydrazones |
JPH04230389A (en) * | 1990-07-16 | 1992-08-19 | American Home Prod Corp | Rapamycin derivative |
US5023264A (en) * | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
US5023263A (en) * | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
US5023262A (en) * | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
US5221670A (en) * | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
US5130307A (en) * | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
PT98990A (en) * | 1990-09-19 | 1992-08-31 | American Home Prod | PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN |
US5358944A (en) * | 1990-09-19 | 1994-10-25 | American Home Products Corporation | Rapamycin esters for treating transplantation rejection |
US5233036A (en) * | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
US5120842A (en) * | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) * | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5194447A (en) * | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
US5118678A (en) * | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
FI921595A (en) * | 1991-04-17 | 1992-10-18 | American Home Prod | RAPAMYCINKARBAMATER |
US5091389A (en) * | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
US5102876A (en) * | 1991-05-07 | 1992-04-07 | American Home Products Corporation | Reduction products of rapamycin |
US5138051A (en) * | 1991-08-07 | 1992-08-11 | American Home Products Corporation | Rapamycin analogs as immunosuppressants and antifungals |
US5776943A (en) * | 1991-05-14 | 1998-07-07 | American Home Products Corporation | Rapamycin metabolites |
US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
EP0516347A1 (en) * | 1991-05-29 | 1992-12-02 | American Home Products Corporation | Rapamycin derivatives |
ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
US5162333A (en) * | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
US5151413A (en) * | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
US5164399A (en) * | 1991-11-18 | 1992-11-17 | American Home Products Corporation | Rapamycin pyrazoles |
US5262424A (en) * | 1992-02-18 | 1993-11-16 | American Home Products Corporation | Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith |
US5177203A (en) * | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
ZA935111B (en) * | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
US5256790A (en) * | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
CA2106034A1 (en) * | 1992-09-24 | 1994-03-25 | Ralph J. Russo | 21-norrapamycin |
US5480988A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
US5434260A (en) * | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
US5480989A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
US5489680A (en) * | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
US5262423A (en) * | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
US5260300A (en) * | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
US5349060A (en) * | 1993-01-07 | 1994-09-20 | American Home Products Corporation | Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents |
US5252579A (en) * | 1993-02-16 | 1993-10-12 | American Home Products Corporation | Macrocyclic immunomodulators |
ES2295093T3 (en) | 1993-04-23 | 2008-04-16 | Wyeth | CONJUGATES AND RAPAMYCIN ANTIBODIES. |
US7279561B1 (en) | 1993-04-23 | 2007-10-09 | Wyeth | Anti-rapamycin monoclonal antibodies |
US5504091A (en) * | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
USRE37421E1 (en) | 1993-07-16 | 2001-10-23 | Smithkline Beecham Corporation | Rapamycin derivatives |
US5387680A (en) * | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
US5373014A (en) * | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
US5391730A (en) * | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
US5378836A (en) * | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
US5385909A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
US5385910A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
US5389639A (en) * | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
US5525610A (en) * | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5463048A (en) * | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
WO1996006847A1 (en) * | 1994-08-31 | 1996-03-07 | Pfizer Inc. | Process for preparing demethylrapamycins |
US5491231A (en) * | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
US5563145A (en) * | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
US5780462A (en) * | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
WO1998002441A2 (en) * | 1996-07-12 | 1998-01-22 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
US5922730A (en) * | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
US7399480B2 (en) | 1997-09-26 | 2008-07-15 | Abbott Laboratories | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices |
US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
US20030129215A1 (en) * | 1998-09-24 | 2003-07-10 | T-Ram, Inc. | Medical devices containing rapamycin analogs |
US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
US20060198867A1 (en) * | 1997-09-25 | 2006-09-07 | Abbott Laboratories, Inc. | Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy |
US8257726B2 (en) * | 1997-09-26 | 2012-09-04 | Abbott Laboratories | Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices |
US7357942B2 (en) * | 1997-09-26 | 2008-04-15 | Abbott Laboratories | Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens |
US8394398B2 (en) * | 1997-09-26 | 2013-03-12 | Abbott Laboratories | Methods of administering rapamycin analogs with anti-inflammatories using medical devices |
US8057816B2 (en) * | 1997-09-26 | 2011-11-15 | Abbott Laboratories | Compositions and methods of administering paclitaxel with other drugs using medical devices |
US7378105B2 (en) * | 1997-09-26 | 2008-05-27 | Abbott Laboratories | Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens |
US8257725B2 (en) * | 1997-09-26 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
US20060240070A1 (en) * | 1998-09-24 | 2006-10-26 | Cromack Keith R | Delivery of highly lipophilic agents via medical devices |
US7455853B2 (en) * | 1998-09-24 | 2008-11-25 | Abbott Cardiovascular Systems Inc. | Medical devices containing rapamycin analogs |
US8257724B2 (en) * | 1998-09-24 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
US7960405B2 (en) * | 1998-09-24 | 2011-06-14 | Abbott Laboratories | Compounds and methods for treatment and prevention of diseases |
US6331547B1 (en) | 1999-08-18 | 2001-12-18 | American Home Products Corporation | Water soluble SDZ RAD esters |
US7807211B2 (en) * | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US20070032853A1 (en) * | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US6790228B2 (en) * | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
US6670355B2 (en) | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
JP2004507465A (en) | 2000-08-11 | 2004-03-11 | ワイス | Methods of treating estrogen receptor positive carcinoma |
ATE411321T1 (en) | 2000-09-19 | 2008-10-15 | Wyeth Corp | WATER SOLUBLE RAPAMYCIN ESTERS |
US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
US6399626B1 (en) | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20080145402A1 (en) * | 2001-09-10 | 2008-06-19 | Abbott Cardiovascular Systems Inc. | Medical Devices Containing Rapamycin Analogs |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
US6939376B2 (en) | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US7682387B2 (en) | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US20040024450A1 (en) * | 2002-04-24 | 2004-02-05 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
JP2005537285A (en) * | 2002-07-30 | 2005-12-08 | ワイス | Parenteral preparations containing rapamycin hydroxy ester |
JP2005537854A (en) * | 2002-09-06 | 2005-12-15 | アボット・ラボラトリーズ | Medical device comprising a hydration inhibitor |
EP2517730A3 (en) * | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
US7160867B2 (en) | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
JP2007505932A (en) * | 2003-09-18 | 2007-03-15 | マクサイト, インコーポレイテッド | Transscleral delivery |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
US7349971B2 (en) * | 2004-02-05 | 2008-03-25 | Scenera Technologies, Llc | System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information |
US20100030183A1 (en) * | 2004-03-19 | 2010-02-04 | Toner John L | Method of treating vascular disease at a bifurcated vessel using a coated balloon |
US8431145B2 (en) | 2004-03-19 | 2013-04-30 | Abbott Laboratories | Multiple drug delivery from a balloon and a prosthesis |
US20070027523A1 (en) * | 2004-03-19 | 2007-02-01 | Toner John L | Method of treating vascular disease at a bifurcated vessel using coated balloon |
WO2005089855A1 (en) * | 2004-03-19 | 2005-09-29 | Abbott Laboratories | Multiple drug delivery from a balloon and a prosthesis |
ATE410431T1 (en) * | 2004-04-14 | 2008-10-15 | Wyeth Corp | METHOD FOR PRODUCING RAPAMYCIN-42 ESTERS AND FK-506-32 ESTERS WITH DICARBONIC ACID, PRECURSORS FOR RAPAMYCIN CONJUGATES AND ANTIBODIES |
EP1737869A1 (en) | 2004-04-14 | 2007-01-03 | Wyeth a Corporation of the State of Delaware | Regiospecific synthesis of rapamycin 42-ester derivatives |
BRPI0510277A (en) * | 2004-04-27 | 2007-10-30 | Wyeth Corp | method for specifically labeling a rapamycin, specifically labeled rapamycin, composition, and kit |
WO2006080951A2 (en) * | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
GT200500216A (en) * | 2004-08-10 | 2006-03-02 | DERIVATIVES OF CCI-779 AND METHODS FOR PREPARATION | |
US7901451B2 (en) | 2004-09-24 | 2011-03-08 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
BRPI0516308A2 (en) * | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | fluid composition, methods of treating a disease or dysfunction, methods of local or systemic release of a biological agent, implants, method of forming an implant, biological agent kit and uses of a fluid composition |
US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
CN101048152A (en) * | 2004-10-28 | 2007-10-03 | 惠氏公司 | Use of an mTOR inhibitor in treatment of uterine leiomyoma |
JP2008530127A (en) | 2005-02-09 | 2008-08-07 | マクサイト, インコーポレイテッド | Formulation for eye treatment |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
CN103143069B (en) * | 2005-02-18 | 2016-05-04 | 阿布拉西斯生物科学公司 | Be used for the medicine of the improved hydrophobicity of incorporation in medical devices |
GB0503936D0 (en) | 2005-02-25 | 2005-04-06 | San Raffaele Centro Fond | Method |
US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
WO2006101845A2 (en) * | 2005-03-16 | 2006-09-28 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
WO2007032777A2 (en) | 2005-03-23 | 2007-03-22 | Abbott Laboratories | Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy |
WO2006102359A2 (en) | 2005-03-23 | 2006-09-28 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
ES2539250T3 (en) | 2005-07-25 | 2015-06-29 | Emergent Product Development Seattle, Llc | Reduction of B cells through the use of CD37 specific binding and CD20 specific binding molecules |
WO2007022494A2 (en) * | 2005-08-19 | 2007-02-22 | Endocyte, Inc. | Multi-drug ligand conjugates |
BRPI0618042A2 (en) | 2005-11-04 | 2011-08-16 | Wyeth Corp | uses of a rapamycin and herceptin, product, pharmaceutical package, and, pharmaceutical composition |
NZ568694A (en) | 2005-11-09 | 2011-09-30 | Zalicus Inc | Method, compositions, and kits for the treatment of medical conditions |
BRPI0620213A2 (en) * | 2005-12-20 | 2011-11-01 | Wyeth Corp | method for preparing a rapamycin composition having increased potency. |
AU2007212271B2 (en) | 2006-02-09 | 2012-11-01 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
US7678901B2 (en) | 2006-02-28 | 2010-03-16 | Wyeth | Rapamycin analogs containing an antioxidant moiety |
US20070203169A1 (en) * | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same |
US7622477B2 (en) * | 2006-02-28 | 2009-11-24 | Cordis Corporation | Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same |
WO2007112052A2 (en) * | 2006-03-23 | 2007-10-04 | Macusight, Inc. | Formulations and methods for vascular permeability-related diseases or conditions |
US20080051691A1 (en) * | 2006-08-28 | 2008-02-28 | Wyeth | Implantable shunt or catheter enabling gradual delivery of therapeutic agents |
EP2083834B1 (en) | 2006-09-13 | 2017-06-21 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
CA2664697A1 (en) | 2006-09-28 | 2008-04-10 | Follica, Inc. | Methods, kits, and compositions for generating new hair follicles and growing hair |
US20080097591A1 (en) | 2006-10-20 | 2008-04-24 | Biosensors International Group | Drug-delivery endovascular stent and method of use |
US8067055B2 (en) * | 2006-10-20 | 2011-11-29 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method of use |
US20080103584A1 (en) * | 2006-10-25 | 2008-05-01 | Biosensors International Group | Temporal Intraluminal Stent, Methods of Making and Using |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8414910B2 (en) * | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US20080175887A1 (en) * | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US10265407B2 (en) | 2007-02-15 | 2019-04-23 | Yale University | Modular nanodevices for smart adaptable vaccines |
US20100104626A1 (en) | 2007-02-16 | 2010-04-29 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
US20100151436A1 (en) * | 2007-03-02 | 2010-06-17 | Fong Peter M | Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles |
CN101678124A (en) | 2007-03-14 | 2010-03-24 | 恩多塞特公司 | Binding ligand linked drug delivery conjugates of tubulysins |
TW200901989A (en) | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
JP2008305262A (en) * | 2007-06-08 | 2008-12-18 | Konica Minolta Business Technologies Inc | Printer introduction method in server and thin client environment |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
EP3569251A1 (en) | 2007-06-25 | 2019-11-20 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
JP2010532764A (en) * | 2007-07-06 | 2010-10-14 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Binding peptide having a specific binding domain located at the C-terminus |
KR100930167B1 (en) * | 2007-09-19 | 2009-12-07 | 삼성전기주식회사 | Ultra wide angle optical system |
EP2278966B1 (en) * | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
US20090253733A1 (en) * | 2008-04-02 | 2009-10-08 | Biointeractions, Ltd. | Rapamycin carbonate esters |
NZ603059A (en) * | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
WO2010021681A2 (en) * | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
CN102231969A (en) * | 2008-10-03 | 2011-11-02 | 万能医药公司 | Macrocyclic lactone compounds and methods for their use |
US20120064143A1 (en) | 2008-11-11 | 2012-03-15 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
US20110312916A1 (en) | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
KR20120115237A (en) | 2009-10-30 | 2012-10-17 | 어리어드 파마슈티칼스, 인코포레이티드 | Methods and compositions for treating cancer |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
US20110130711A1 (en) * | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
US8951595B2 (en) * | 2009-12-11 | 2015-02-10 | Abbott Cardiovascular Systems Inc. | Coatings with tunable molecular architecture for drug-coated balloon |
US8480620B2 (en) * | 2009-12-11 | 2013-07-09 | Abbott Cardiovascular Systems Inc. | Coatings with tunable solubility profile for drug-coated balloon |
US20110144577A1 (en) * | 2009-12-11 | 2011-06-16 | John Stankus | Hydrophilic coatings with tunable composition for drug coated balloon |
EA201290876A1 (en) | 2010-03-05 | 2013-03-29 | Президент Энд Феллоуз Оф Гарвард Колледж | COMPOSITIONS OF INDUCED DENDRITIC CELLS AND THEIR USE |
RU2603261C2 (en) | 2011-04-01 | 2016-11-27 | Сандоз Аг | Regioselective acylation of rapamycin at c-42 position |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
WO2013013708A1 (en) | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Treatment of acute rejection in renal transplant |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
WO2013163176A1 (en) | 2012-04-23 | 2013-10-31 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
ES2574522T3 (en) | 2012-06-08 | 2016-06-20 | Biotronik Ag | 40-O-cyclic rapamycin hydrocarbon esters, compositions and procedures |
CN103705925B (en) | 2012-09-29 | 2018-03-30 | 段磊 | Suppress the drug regimen of PI3K/AKT/mTOR signal paths |
US9750728B2 (en) | 2012-09-29 | 2017-09-05 | Targeted Therapeutics, Llc | Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway |
CA2926747A1 (en) | 2012-10-12 | 2014-04-17 | Arlan RICHARDSON | Use of mtor inhibitors to treat vascular cognitive impairment |
EA201590622A1 (en) | 2012-10-16 | 2015-10-30 | Эндосайт, Инк. | CONJUGATES FOR DELIVERY OF MEDICINES CONTAINING NOT MEETING IN THE NATURE OF AMINO ACID AND METHODS OF APPLICATION |
US20150258127A1 (en) | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
EP4066841A1 (en) | 2013-03-14 | 2022-10-05 | University of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
KR102233251B1 (en) | 2013-04-03 | 2021-03-26 | 엔-폴드 엘엘씨 | Novel nanoparticle compositions |
CN105636594A (en) | 2013-08-12 | 2016-06-01 | 托凯药业股份有限公司 | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
DK3089737T3 (en) | 2013-12-31 | 2021-12-13 | Rapamycin Holdings Llc | ORAL RAPAMYCIN NANOPARTICLE PREPARATIONS AND USE. |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
CA2968049A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
EP3193902A4 (en) | 2014-09-11 | 2018-03-28 | The Regents of The University of California | mTORC1 INHIBITORS |
WO2017029391A1 (en) | 2015-08-20 | 2017-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating cancer |
US20210154372A1 (en) | 2017-05-15 | 2021-05-27 | C.R. Bard, Inc. | Medical device with drug-eluting coating and intermediate layer |
US20200129486A1 (en) | 2017-06-26 | 2020-04-30 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of olmsted syndrome |
US20210147801A1 (en) | 2017-07-13 | 2021-05-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/- tregs |
AR112834A1 (en) | 2017-09-26 | 2019-12-18 | Novartis Ag | RAPAMYCIN DERIVATIVES |
FI3788049T3 (en) | 2018-05-01 | 2023-05-30 | Revolution Medicines Inc | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors |
MX2020011564A (en) | 2018-05-01 | 2021-01-29 | Revolution Medicines Inc | C26-linked rapamycin analogs as mtor inhibitors. |
WO2020023417A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
CN113164557A (en) | 2018-07-23 | 2021-07-23 | 因柯利尔疗法公司 | Methods of treating neurological disorders |
EP3849545A1 (en) | 2018-09-10 | 2021-07-21 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of neurofibromatosis |
EP3880266A1 (en) | 2018-11-14 | 2021-09-22 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
US20220176084A1 (en) | 2019-04-08 | 2022-06-09 | Bard Peripheral Vascular, Inc. | Medical device with drug-eluting coating on modified device surface |
KR20220011123A (en) | 2019-04-11 | 2022-01-27 | 엔클리어 테라피스, 인크. | Cerebrospinal fluid improvement method and device and system therefor |
WO2024008799A1 (en) | 2022-07-06 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of proliferative glomerulonephritis |
WO2024028433A1 (en) | 2022-08-04 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
DE2333298C3 (en) * | 1973-06-29 | 1978-05-03 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Circuit arrangement for converting analog signals into PCM signals and from PCM signals into analog signals |
US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
BE877700A (en) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | PHARMACEUTICAL COMPOSITIONS BASED ON RAPAMYCIN FOR THE TREATMENT OF CARCINOGENIC TUMORS |
-
1980
- 1980-08-25 US US06/181,252 patent/US4316885A/en not_active Expired - Lifetime
-
1981
- 1981-07-30 CA CA000382848A patent/CA1159054A/en not_active Expired
- 1981-08-20 EP EP81303794A patent/EP0046661B1/en not_active Expired
- 1981-08-20 AT AT81303794T patent/ATE7920T1/en not_active IP Right Cessation
- 1981-08-20 DE DE8181303794T patent/DE3164177D1/en not_active Expired
- 1981-08-21 IE IE1919/81A patent/IE51508B1/en unknown
- 1981-08-24 JP JP56133225A patent/JPS57118586A/en active Pending
Non-Patent Citations (1)
Title |
---|
Chemical Abstract, vol. 90, 1979 Columbus, Ohio, USA, H. Baker et al. "Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation", page 36, abstract no. 351y * |
Also Published As
Publication number | Publication date |
---|---|
CA1159054A (en) | 1983-12-20 |
IE811919L (en) | 1982-02-25 |
IE51508B1 (en) | 1987-01-07 |
ATE7920T1 (en) | 1984-06-15 |
US4316885A (en) | 1982-02-23 |
JPS57118586A (en) | 1982-07-23 |
EP0046661A1 (en) | 1982-03-03 |
DE3164177D1 (en) | 1984-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0046661B1 (en) | Rapamycin derivatives | |
US4308268A (en) | Maytansinoids, pharmaceutical compositions thereof and method of use thereof | |
EP0665846B1 (en) | Topoisomerase ii inhibitors and therapeutic uses therefor | |
KR101555860B1 (en) | Rifamycin derivatives | |
CZ299840B6 (en) | Novel aromatic amides, process of their preparation and their use as medicaments | |
YAMASHITA et al. | Saintopin, a new antitumor antibiotic with topoisomerase II dependent DNA cleavage activity, from Paecilomyces | |
US5215980A (en) | 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof | |
FI68057C (en) | FOERFARANDE FOER FRAMSTAELLNING AV ANTRACYKLINDERIVAT | |
Tatsuta et al. | The Total Synthesis of a Glycosidase Inhibitor, Nagstatin. | |
US4859782A (en) | Misakinolide compositions and their derivatives | |
Kirschning et al. | Syntheses and biological evaluation of new glyco-modified angucyclin-antibiotics | |
US5994365A (en) | Substituted diazaanthracene compounds having pharmaceutical utility | |
Zhang et al. | Antitumor Agents, 130. Novel 4β-Arylamino Derivatives of 3', 4'-Didemethoxy-3', 4'-dioxo-4-deoxypodophyllotoxin as Potent Inhibitors of Human DNA Topoisomerase II | |
Taylor et al. | Synthesis and antifungal selectivity of new derivatives of amphotericin B modified at the C-13 position | |
DK152677B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF 4'-O-TETRA-HYDROPYRANYLADRIAMYCINE OR A POISONOUS ACID ADDITION SALT | |
US4560703A (en) | Clavulone derivatives, process for preparing the same, and use of said compounds | |
US4100277A (en) | 4,1-Benzoxazonine derivatives and process therefor | |
Carter et al. | LL-E19020α and β novel growth promoting agents: Isolation, characterization and structures | |
US5023079A (en) | Heptaene V-28-3 antibiotic derivative | |
RU2523284C2 (en) | Method for modification of macrolide antibiotic oligomycin a by reaction of [3+2]-dipolar cycloconnection of azide and alkines 33-deoxy-33-(triazol-1-yl)-oligomycins a and their biological activity | |
CA1286288C (en) | Diels-alder adduct from streptazoline and naphthoquinones andits oxidation products, a process for their preparation and their use | |
EP0052238B1 (en) | A new vincamine derivative, a method for its preparation and pharmaceutical compositions containing it | |
PT99418A (en) | METHOD FOR PREPARING THE ANTIBIOTIC ANTITUMOR DINEMICIN C AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
US3654303A (en) | 5-bromo-4-oxo-4 5 6 7-tetrahydroindoles and methods of preparing same | |
KR100533244B1 (en) | Cytotoxic Alkaloid Derivatives Including Asmarine A and B Isolated from a Sponge |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19820809 |
|
ITF | It: translation for a ep patent filed |
Owner name: BARZANO' E ZANARDO MILANO S.P.A. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AYERST, MCKENNA AND HARRISON INC. |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 7920 Country of ref document: AT Date of ref document: 19840615 Kind code of ref document: T |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19840630 Year of fee payment: 4 |
|
REF | Corresponds to: |
Ref document number: 3164177 Country of ref document: DE Date of ref document: 19840719 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19840731 Year of fee payment: 4 |
|
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19840831 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19840831 Year of fee payment: 4 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19840930 Year of fee payment: 4 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19841026 Year of fee payment: 4 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19850816 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19850831 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Effective date: 19860820 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19860821 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19860831 Ref country code: CH Effective date: 19860831 |
|
BERE | Be: lapsed |
Owner name: AYERST MCKENNA AND HARRISON INC. Effective date: 19860831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19870301 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19870430 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19870501 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19881118 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19890831 |
|
EUG | Se: european patent has lapsed |
Ref document number: 81303794.2 Effective date: 19870812 |